Clinical Trials Logo

Polycystic Ovary Syndrome clinical trials

View clinical trials related to Polycystic Ovary Syndrome.

Filter by:

NCT ID: NCT06158932 Completed - Clinical trials for Polycystic Ovary Syndrome

A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance

Start date: September 8, 2023
Phase: N/A
Study type: Interventional

This is a virtual single group study that will last 12 weeks. 40 female participants will take 4 capsules of the Optify Myo Inositol and D-Chiro Inositol Plus Folate and Vitamin D supplement per day. Questionnaires will be completed at Baseline, Week 4, Week 8 and Week 12. Participants will also provide a waist circumference measurement at Baseline and Week 12.

NCT ID: NCT06140108 Completed - Clinical trials for Polycystic Ovary Syndrome

Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity

Start date: December 15, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

this is open labelled randomize control trial among women with PCOS. PCOS, an endocrine condition, affects 5%-15% of premenopausal women. PCOS is characterized by atypical menstruation, ovulation difficulties, hyperandrogenemia, insulin resistance, and other metabolic abnormalities. Metformin is now an option for PCOS. The clinical reactions to metformin are limited and varied. Novel SGLT2 inhibitors treat type 2 diabetes with weight loss, insulin resistance reduction, and cardiovascular benefits. There is little evidence on SGLT2 inhibitor effectiveness in PCOS patients.

NCT ID: NCT06056453 Completed - Clinical trials for Polycystic Ovary Syndrome

Interpersonal Psychotherapy in Adolescents With Polycystic Ovary Syndrome

IPAP
Start date: September 20, 2021
Phase: N/A
Study type: Interventional

The main purpose of this study is to find out whether taking part in a group-based interpersonal psychotherapy (IPT) program designed to improve mood and lessen stress in girls with PCOS will improve depression, unhealthy eating behaviors, weight, and insulin resistance.

NCT ID: NCT06031753 Completed - Insulin Resistance Clinical Trials

Effects of Intermittent Fasting on Polycystic Ovary Syndrome (PCOS) Compared to Standard Treatment

Start date: June 3, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the effects of Time restricted eating in patients diagnosed with polycystic ovary syndrome, comparing it to the standard hormonal treatment.

NCT ID: NCT06015594 Completed - Clinical trials for Polycystic Ovary Syndrome

Metformin Treatment in Adolescent Patients With PCOS: A Long-term, Winning Metabolic Choice.

Start date: January 1, 2015
Phase: N/A
Study type: Interventional

This study aimed to understand whether metformin therapy can improve insulin resistance in adolescent PCOS patients, both during treatment and after discontinuation, and to evaluate its action on the hormonal and metabolic pathways.

NCT ID: NCT06009172 Completed - Clinical trials for Polycystic Ovary Syndrome

APA on Sleep Quality in Women With PCOS

Start date: July 24, 2022
Phase: N/A
Study type: Interventional

Women with polycystic ovary syndrome (PCOS) appear to have an increased frequency of sleep problems. The aim of this study was to explore the effect of auricular point acupressure (APA) pressure on sleep quality in women with PCOS.

NCT ID: NCT05981742 Completed - Clinical trials for Polycystic Ovary Syndrome

Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS

Start date: September 21, 2022
Phase: Phase 2
Study type: Interventional

The goal of this interventional Randomized clinical is to compare the effect of Metformin alone, Cabergoline alone and Metformin and Cabergoline in combination in a sample of Iraqi female patients with polycystic ovary syndrome. The main questions to answer are: 1. What are the effects of the tested regimens on Body mass index (BMI)? 2. What are the effects of the tested regimens on hormonal status? 3. What are the effects of the tested regimens on uterine artery resistive index ? 4. What are the effects of the tested regimens on some inflammatory markers? Participants will be separated into two groups: 1. Group 1 (M): 25 Patients, Received Metformin 500mg per oral twice daily for 90 days duration. 2. Group 2 (D): 25 Patients, Received Dostinex (Pergolin) 0.5 mg per oral (single dose per/week). 3. Group 3 (MD): 25 Pateins, Received metformin 500 mg per oral twice daily for 90 days duration and Dostinex (Pergolin) as 0.5 mg per oral (single dose per/week). Researchers will compare Group 1 (M), Group 2 (D), Group 3 (MD) to observe the effect of the tested treatment regimens on Body Mass Index, Hormonal status, uterine artery resistive index, and some inflammatory markers that are IL-18, Anti-GAD Antibody and GnRH Antibody.

NCT ID: NCT05843955 Completed - NAFLD Clinical Trials

Non-alcoholic Fatty Liver Disease in Women With Polycystic Ovary Syndrome

Start date: September 1, 2015
Phase:
Study type: Observational

This study was planned to examine the prevalence of vitamin D insufficiency, insulin resistance, non-alcoholic fatty liver disease (NAFLD), and their relationship with each other and the nutritional status of individuals with polycystic ovary syndrome (PCOS) in reproductive age, by evaluating anthropometric, biochemical, and ultrasonographic findings and food consumption frequency data.

NCT ID: NCT05840692 Completed - Clinical trials for Polycystic Ovary Syndrome

The Effect of Escitalopram in PCOS

Start date: August 2013
Phase: Phase 4
Study type: Interventional

In a randomized study the investigators aim to characterize the effect of antidepressive medicine on quality of life, body composition, adrenal activity and glucose metabolism in PCOS. PCOS is a common endocrine disorder characterized by adrenal and ovarian hyperandrogenaemia, anovulation and insulin resistance. The pathogenesis of PCOS may be described by a vicious cycle involving insulin resistance which stimulates ovarian and adrenal hyper androgenaemia and leads to abdominal obesity, causing increased risk for diabetes and cardiovascular disease. Adrenal hyperactivity is associated with depression. Antidepressive medicine may normalize pituitary-adrenal activity and in animal studies antidepressive medicine improved adrenal hyperactivity and normalized insulin sensitivity.

NCT ID: NCT05802212 Completed - Clinical trials for PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries

Effect of Metformin on Patients With Polycystic Ovary Syndrome

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

The purpose of the study is to understand the effect of Metformin on patients with PCOS.